Tardive Dyskinesia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major tardive dyskinesia markets reached a value of US$ 1.7 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 2.4 Billion by 2034, exhibiting a growth rate (CAGR) of 3.07% during 2024-2034.
The tardive dyskinesia market has been comprehensively analyzed in IMARC's new report titled "Tardive Dyskinesia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Tardive dyskinesia (TD) is a neurological disorder characterized by repetitive, involuntary movements that typically affect the face, mouth, and tongue but can also involve the limbs and torso. These movements may include grimacing, tongue protrusion, lip smacking, rapid eye blinking, and jerky movements of the arms and legs. The condition may disrupt people's lives, impacting their emotional and social well-being. Individuals suffering from this ailment may experience symptoms like finger wiggling, foot tapping, the flapping of arms, swaying from side to side, thrusting out the pelvis, etc. The diagnosis of TD is typically based on a review of the patient's clinical features and medical history. A physical exam, such as the Abnormal Involuntary Movement Scale (AIMS), can also be utilized to rate any abnormal movements and determine disease severity among patients. Other frequently performed diagnostic tests and procedures include blood workups, cerebral computed tomography (CT) scans, magnetic resonance imaging (MRI), etc.
The rising cases of mental illnesses that require prolonged treatment with antipsychotic drugs, causing irregular dopamine signaling in a specific part of the brain, are primarily driving the tardive dyskinesia market. In addition to this, the escalating adoption of neuropsychological testing for detecting changes in cognitive function, speed of information processing, and identifying specific patterns of impairment consistent with the condition is also propelling the market growth. Furthermore, the widespread utilization of deep brain stimulation therapy to treat this ailment, owing to its various advantages, such as its nondestructive nature, reversibility, adjustability, and rapid and long-term symptom relief, is creating a positive outlook for the market. Additionally, the continuous advancements in clinical studies that encourage the launch of novel products and the introduction of favorable guidelines to enable early approval of pipeline drugs for neurological movement disorders are also bolstering the market growth. Moreover, the emerging popularity of vesicular monoamine transporter 2 inhibitors, including tetrabenazine, valbenazine, deutetrabenazine, etc., which alter particular proteins and deplete the transport of dopamine, thereby reducing its release and breakdown by monoamine oxidase, is further expected to drive the tardive dyskinesia market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the tardive dyskinesia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for tardive dyskinesia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the tardive dyskinesia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the tardive dyskinesia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the tardive dyskinesia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current tardive dyskinesia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the tardive dyskinesia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the tardive dyskinesia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the tardive dyskinesia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of tardive dyskinesia across the seven major markets?
What is the number of prevalent cases (2018-2034) of tardive dyskinesia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of tardive dyskinesia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with tardive dyskinesia across the seven major markets?
What is the size of the tardive dyskinesia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of tardive dyskinesia?
What will be the growth rate of patients across the seven major markets?
Tardive Dyskinesia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for tardive dyskinesia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the tardive dyskinesia market?
What are the key regulatory events related to the tardive dyskinesia market?
What is the structure of clinical trial landscape by status related to the tardive dyskinesia market?
What is the structure of clinical trial landscape by phase related to the tardive dyskinesia market?
What is the structure of clinical trial landscape by route of administration related to the tardive dyskinesia market?
The tardive dyskinesia market has been comprehensively analyzed in IMARC's new report titled "Tardive Dyskinesia Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Tardive dyskinesia (TD) is a neurological disorder characterized by repetitive, involuntary movements that typically affect the face, mouth, and tongue but can also involve the limbs and torso. These movements may include grimacing, tongue protrusion, lip smacking, rapid eye blinking, and jerky movements of the arms and legs. The condition may disrupt people's lives, impacting their emotional and social well-being. Individuals suffering from this ailment may experience symptoms like finger wiggling, foot tapping, the flapping of arms, swaying from side to side, thrusting out the pelvis, etc. The diagnosis of TD is typically based on a review of the patient's clinical features and medical history. A physical exam, such as the Abnormal Involuntary Movement Scale (AIMS), can also be utilized to rate any abnormal movements and determine disease severity among patients. Other frequently performed diagnostic tests and procedures include blood workups, cerebral computed tomography (CT) scans, magnetic resonance imaging (MRI), etc.
The rising cases of mental illnesses that require prolonged treatment with antipsychotic drugs, causing irregular dopamine signaling in a specific part of the brain, are primarily driving the tardive dyskinesia market. In addition to this, the escalating adoption of neuropsychological testing for detecting changes in cognitive function, speed of information processing, and identifying specific patterns of impairment consistent with the condition is also propelling the market growth. Furthermore, the widespread utilization of deep brain stimulation therapy to treat this ailment, owing to its various advantages, such as its nondestructive nature, reversibility, adjustability, and rapid and long-term symptom relief, is creating a positive outlook for the market. Additionally, the continuous advancements in clinical studies that encourage the launch of novel products and the introduction of favorable guidelines to enable early approval of pipeline drugs for neurological movement disorders are also bolstering the market growth. Moreover, the emerging popularity of vesicular monoamine transporter 2 inhibitors, including tetrabenazine, valbenazine, deutetrabenazine, etc., which alter particular proteins and deplete the transport of dopamine, thereby reducing its release and breakdown by monoamine oxidase, is further expected to drive the tardive dyskinesia market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the tardive dyskinesia market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for tardive dyskinesia and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the tardive dyskinesia market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the tardive dyskinesia market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the tardive dyskinesia market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current tardive dyskinesia marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the tardive dyskinesia market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the tardive dyskinesia market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the tardive dyskinesia market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of tardive dyskinesia across the seven major markets?
What is the number of prevalent cases (2018-2034) of tardive dyskinesia by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of tardive dyskinesia by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with tardive dyskinesia across the seven major markets?
What is the size of the tardive dyskinesia patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of tardive dyskinesia?
What will be the growth rate of patients across the seven major markets?
Tardive Dyskinesia: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for tardive dyskinesia drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the tardive dyskinesia market?
What are the key regulatory events related to the tardive dyskinesia market?
What is the structure of clinical trial landscape by status related to the tardive dyskinesia market?
What is the structure of clinical trial landscape by phase related to the tardive dyskinesia market?
What is the structure of clinical trial landscape by route of administration related to the tardive dyskinesia market?
?1 Preface
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 TARDIVE DYSKINESIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 TARDIVE DYSKINESIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 TARDIVE DYSKINESIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 TARDIVE DYSKINESIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 TARDIVE DYSKINESIA - UNMET NEEDS
10 TARDIVE DYSKINESIA - KEY ENDPOINTS OF TREATMENT
11 TARDIVE DYSKINESIA - MARKETED PRODUCTS
11.1 List of Tardive Dyskinesia Marketed Drugs Across the Top 7 Markets
11.1.1 Ingrezza (Valbenazine) - Neurocrine Biosciences
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Austedo (Deutetrabenazine) - Teva Pharmaceutical
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 TARDIVE DYSKINESIA - PIPELINE DRUGS
12.1 List of Tardive Dyskinesia Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. TARDIVE DYSKINESIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. TARDIVE DYSKINESIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 TARDIVE DYSKINESIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Tardive Dyskinesia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Tardive Dyskinesia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Tardive Dyskinesia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Tardive Dyskinesia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Tardive Dyskinesia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Tardive Dyskinesia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Tardive Dyskinesia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Tardive Dyskinesia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Tardive Dyskinesia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Tardive Dyskinesia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Tardive Dyskinesia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Tardive Dyskinesia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Tardive Dyskinesia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Tardive Dyskinesia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Tardive Dyskinesia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Tardive Dyskinesia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Tardive Dyskinesia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Tardive Dyskinesia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Tardive Dyskinesia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Tardive Dyskinesia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Tardive Dyskinesia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Tardive Dyskinesia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Tardive Dyskinesia - Access and Reimbursement Overview
16 TARDIVE DYSKINESIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 TARDIVE DYSKINESIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 TARDIVE DYSKINESIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 TARDIVE DYSKINESIA - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 TARDIVE DYSKINESIA - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 TARDIVE DYSKINESIA - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 TARDIVE DYSKINESIA - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 TARDIVE DYSKINESIA - UNMET NEEDS
10 TARDIVE DYSKINESIA - KEY ENDPOINTS OF TREATMENT
11 TARDIVE DYSKINESIA - MARKETED PRODUCTS
11.1 List of Tardive Dyskinesia Marketed Drugs Across the Top 7 Markets
11.1.1 Ingrezza (Valbenazine) - Neurocrine Biosciences
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Austedo (Deutetrabenazine) - Teva Pharmaceutical
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 TARDIVE DYSKINESIA - PIPELINE DRUGS
12.1 List of Tardive Dyskinesia Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13. TARDIVE DYSKINESIA - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. TARDIVE DYSKINESIA – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 TARDIVE DYSKINESIA - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Tardive Dyskinesia - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Tardive Dyskinesia - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Tardive Dyskinesia - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Tardive Dyskinesia - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Tardive Dyskinesia - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Tardive Dyskinesia - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Tardive Dyskinesia - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Tardive Dyskinesia - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Tardive Dyskinesia - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Tardive Dyskinesia - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Tardive Dyskinesia - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Tardive Dyskinesia - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Tardive Dyskinesia - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Tardive Dyskinesia - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Tardive Dyskinesia - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Tardive Dyskinesia - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Tardive Dyskinesia - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Tardive Dyskinesia - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Tardive Dyskinesia - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Tardive Dyskinesia - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Tardive Dyskinesia - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Tardive Dyskinesia - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Tardive Dyskinesia - Access and Reimbursement Overview
16 TARDIVE DYSKINESIA - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 TARDIVE DYSKINESIA MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 TARDIVE DYSKINESIA MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
